Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$123.46 USD

123.46
1,033,841

-3.67 (-2.89%)

Updated May 24, 2024 04:00 PM ET

After-Market: $123.49 +0.03 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug

    by Zacks Equity Research

    Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.

      Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up

      by Zacks Equity Research

      Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.

        Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

        by Zacks Equity Research

        Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

          Kevin Cook headshot

          Why Sarepta (SRPT) Jumped and We Sold

          by Kevin Cook

          Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

            Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

            by Zacks Equity Research

            Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

              Kevin Cook headshot

              Healthcare Heroes That Aren't Done Yet

              by Kevin Cook

              Key growth stocks across medical industries tell you the megatrends are in full force for years to come

                Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress

                by Zacks Equity Research

                Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.

                  Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)

                  by Zacks Equity Research

                  Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                    BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat

                    by Zacks Equity Research

                    BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.

                      The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

                        Here's Why Sarepta Stock is Up More Than 70% in 6 Months

                        by Zacks Equity Research

                        Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.

                          Arpita Dutt headshot

                          5 Top-Ranked Drug Stocks that are Broker Favorites

                          by Arpita Dutt

                          With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

                            4 Biotech Stocks to Better Your Financial Health This Winter

                            by Zacks Equity Research

                            The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.

                              Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?

                              by Zacks Equity Research

                              Surging implied volatility makes Sarepta Therapeutics (SRPT) Stock lucrative to the option traders.

                                BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised

                                by Zacks Equity Research

                                BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.

                                  Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised

                                  by Zacks Equity Research

                                  Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.

                                    Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?

                                    by Zacks Equity Research

                                    Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.

                                      What's in Store for BioMarin (BMRN) This Earnings Season?

                                      by Zacks Equity Research

                                      BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.

                                        Catabasis' DMD Candidate Slows Disease Progression, Stock Up

                                        by Zacks Equity Research

                                        Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.

                                          Here's Why Sarepta Stock is Up More Than 60% So Far in 2017

                                          by Zacks Equity Research

                                          Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.

                                            Sarepta's Golodirsen Positive in DMD Study, Shares Soar

                                            by Zacks Equity Research

                                            Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.

                                              Why Is Sarepta (SRPT) Down 9.9% Since the Last Earnings Report?

                                              by Zacks Equity Research

                                              Sarepta (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                Kevin Cook headshot

                                                What You See, and What You Get: The Neurology of Perception

                                                by Kevin Cook

                                                While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.

                                                  BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates

                                                  by Zacks Equity Research

                                                  BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.